BOCA RATON, Fla. (April 28, 2020) – Aventusoft, inventor of the “HEMOTAG CPAS” cardiac diagnostic system, today announced it has been awarded additional $ 3 million funding from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). This SBIR FastTrack grant allows HEMOTAG CPAS to develop a new application for hemodynamic-guided therapy to diagnose and monitor congestive heart failure (CHF) in patients.
Standard patient monitoring methods such as blood pressure, weight, thoracic impedance, stethoscope auscultation or ECG rhythm strips are insufficient to reduce patient readmission. In contrast, pulmonary artery pressure (PAP) is recognized as the key parameter for effective management of CHF and reducing hospitalization rates however, existing technology to measure PAP is expensive or requires invasive procedures.
HEMOTAG CPAS aims to offer an alternate, absolute measurement which can be carried out by non-cardiologist care givers within 2 minutes, is entirely non-invasive and securely engages the patient’s care circle with actionable, specific diagnostic reports. HEMOTAG CPAS’ core technology has already been evaluated through multiple clinical studies and this additional funding allows broadening of the indications for use, giving caregivers a single, modern, compact, wireless system with unprecedented diagnostic power.
“Accurate close monitoring of cardiac patients non-invasively and from their homes is a major advance in the care of this ever-increasing population of heart failure patients. Improved outcomes and reduced hospital admissions, will be greatly beneficial to this group of patients numbered in the millions in this country alone.” – Robert Chait, MD (Program Director Cardiology Fellowship, University of Miami, JFK Medical Center).
Using this funding, HEMOTAG will be studied further in Tier 1 hospitals in South Florida, where the company is located. These trials are planned to be conducted at the Cleveland Clinic and HCA-JFK Hospital, and encompass clinical and health economic outcome data from 420 patients. The trials will be led by investigators Jaime Hernandez-Montfort, MD (Advanced Heart Disease and Transplant Cardiologist, Cleveland Clinic Florida), Robert Cubeddu, MD (Acting Chairman of the Department of Cardiology, Heart and Vascular Institute, Cleveland Clinic Florida), Robert Chait, MD (Program Director Cardiology Fellowship University of Miami, JFK Medical Center), and Waqas Ghumman, MD (Advanced Heart Failure & Transplant Cardiology, JFK Medical Center).
Independent safety and oversight of the clinical trial will be conducted by a highly accomplished committee comprised of Professor Marc Pfeffer, MD, PhD (Dzau Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital), Professor Charles Hennekens, MD (Senior Academic Advisor to the Dean, College of Medicine, Florida Atlantic University), Steven Borzak, MD (Associate Program Director, Cardiology Fellowship, University of Miami Miller School of Medicine at JFK Campus), and Professor Katherine Freeman-Costin, Dr.P.H. (Biostatistics Core Leader, Charles E. Schmidt College of Medicine, Florida Atlantic University).
“The HEMOTAG CPAS team is proud to serve our community by giving our clinician and patient partners cutting-edge telemedicine capabilities, with a cost-effective, ultra-compact and powerful hemodynamic diagnostic system,” stated Kaustubh Kale, Founder & CEO of Aventusoft.
In 2018, Aventusoft was selected by the Research Park at FAU to receive funding to participate in GrowFL’s strategic research economic gardening initiative in recognition of its potential to disrupt its industry and to significantly impact the regional economy.
Download the release here.